以线粒体为靶点治疗肝损伤的研究进展

Research Progress in the Treatment of Liver Injury by Targeting Mitochondria

因线粒体功能损伤引起的肝细胞线粒体功能障碍会引起肝细胞内磷酸腺苷缺乏、活性氧增加、线粒体膜电位降低、线粒体DNA损伤,促发肝细胞凋亡与炎症产生,严重影响到肝细胞生物合成和解毒功能。因此,以线粒体为靶点的治疗策略已经逐渐成为急性肝损伤、肝炎等一系列肝脏疾病防治领域中的研究热点。从线粒体损伤在肝病发生发展中的作用入手,并根据治疗药物维度的不同,从小分子药物、大分子药物、亚细胞器及细胞治疗等不同维度,系统地综述了目前以线粒体为靶点治疗肝脏疾病的研究进展,并对各类策略的优缺点及未来临床前景进行了探讨。

Hepatocyte mitochondrial dysfunction caused by mitochondrial function damage can cause adenosine phosphate deficiency,increased reactive oxygen species,decreased mitochondrial membrane potential and mitochondrial DNA damage in hepatocytes,which can promote apoptosis and inflammation of hepatocytes and seriously affect the biosynthesis and detoxification functions of hepatocytes.Therefore,therapeutic strategies targeting mitochondria have gradually become a research hotspot in the field of prevention and treatment of a series of liver diseases such as acute liver injury and hepatitis.Based on the role of mitochondrial damage in the occurrence and development of liver disease,and according to the dimensions of different treatment drugs,such as small molecules and macromolecular drugs,the organelles and cell therapy,this paper systematically reviews the mitochondria as targets for the treatment of liver disease research progress,and the advantages and disadvantages of all kinds of strategies and future clinical prospects were discussed.